IRELAND UNITED STATES INDIA
Insight / Manufacturing intelligence
In this insight
Industrial data
Automation
Operational performance
Introduction
In the pharmaceutical industry, compliance with regulatory requirements is non-negotiable. One of the cornerstones of maintaining compliance while ensuring product quality is effective batch reporting. However, traditional batch reporting can be time-consuming and labour-intensive, particularly when every detail must be reviewed manually. This is where the concept of Review by Exception (RBE) transforms the process, enabling pharmaceutical manufacturers to focus only on deviations and anomalies rather than analysing every data point.
In this blog, we’ll explore the fundamentals of batch reporting and RBE, their benefits in the pharma industry, and how Réalta Technologies supports this approach using cutting-edge technologies and tools.
What Are Batch Reports in Pharma?
Batch reports are comprehensive documents detailing every stage of a pharmaceutical manufacturing process, from raw material procurement to final product release. These reports serve as critical records for ensuring that each batch of a product complies with stringent regulatory standards, including FDA 21 CFR Part 11 and EU GMP Annex 11.
Batch reports typically include:
While essential for compliance, manually reviewing batch reports is resource-intensive and can delay product release.
What Is Review by Exception (RBE)?
Review by Exception (RBE) is a modern approach to batch reporting that focuses on identifying and analysing deviations or anomalies rather than manually reviewing all data. With this method, only data points or events outside predefined parameters (exceptions) are flagged for review.
RBE eliminates unnecessary reviews of compliant data, streamlining the batch release process while maintaining quality and regulatory adherence.
Benefits of Batch Reports with Review by Exception
RBE drastically reduces the time required for batch reviews by highlighting only the exceptions, enabling faster product release without compromising quality.
By automating the identification of exceptions, RBE allows quality teams to focus their efforts on addressing critical issues, reducing manual workloads.
Automated monitoring and reporting ensure that every deviation is documented and addressed, meeting stringent regulatory requirements.
Dashboards and advanced analytics provide clear insights into trends and recurring exceptions, empowering manufacturers to implement preventive measures.
Streamlined review processes lead to operational efficiencies, reducing costs associated with lengthy manual reviews and production delays.
When a review is performed manually on large quantities of data, the likelihood of missing a deviation is much larger than when with an automated review.
How Réalta Technologies Supports Batch Reporting and RBE
Réalta Technologies is at the forefront of providing pharmaceutical manufacturers with tailored solutions for batch reporting and Review by Exception. By combining industry expertise with advanced technology, we help clients implement efficient, compliant, and scalable systems for managing batch data.
Technologies and Tools We Use:
AVEVA PI System
PI Notifications
PI Batch Interfaces
PI Event Frames (EF Gen)
Syncade MES Integration
RtReports
How Réalta Technologies Can Assist Your Facility
At Réalta Technologies, we specialise in designing and implementing robust solutions for batch reporting and Review by Exception in pharmaceutical manufacturing. Here’s how we can help:
We ensure seamless integration of batch reporting systems with your existing MES, automation, and data collection platforms. This unified approach ensures that all critical data is captured and analysed in real time.
Every facility is unique, and so are its needs. Our team works closely with you to develop RBE parameters and customised dashboards that align with your operations and regulatory requirements.
Using tools like SEEQ and PowerBI, we provide advanced analytics capabilities, enabling you to gain deeper insights into exceptions and optimise your processes accordingly.
As your operations grow, our solutions can scale with you. Whether you’re adding new lines or increasing production capacity, Réalta Technologies ensures your systems remain robust and efficient.
With a deep understanding of pharmaceutical regulations, our team ensures that all batch reporting systems meet compliance requirements, including FDA 21 CFR Part 11 and EU GMP standards.
Conclusion
Batch reporting and Review by Exception are revolutionising the pharmaceutical industry, offering faster, more efficient, and compliant ways to manage batch data. With Réalta Technologies’ expertise and cutting-edge solutions, you can streamline your reporting processes, reduce costs, and ensure compliance with industry regulations.
Contact us today to learn how Réalta Technologies can help your pharmaceutical facility adopt Review by Exception and achieve operational excellence.
Phone: +353 21 243 9113
Email: sales@Realtatechnologies.com
Related thinking
More ideas from Réalta specialists.
Réalta Technologies recently hosted Turning Data into Action at Thomond Park, a unique event bringing together industry and sport to explore how data, AI, and digital transformation are driving performance and operational excellence. With speakers from AVEVA, SolutionsPT, and Munster Rugby, the day delivered valuable insights and collaboration across sectors.
Read more →Réalta Technologies successfully upgraded a pharmaceutical client’s PI System, replacing outdated hardware and operating systems with a modern, compliant, and high-performance infrastructure without losing a single data point.
Read more →Explore how Power BI, Tableau, and SEEQ compare when it comes to visualising data in manufacturing environments. This blog highlights their strengths, weaknesses, and real-world use cases to help you choose the best tool for your business.
Read more →Databricks is a powerful data analytics platform that unifies data engineering, machine learning, and business intelligence at scale. In this blog, we explore what Databricks is, its core features and benefits, and how Réalta Technologies uses it to deliver value across life sciences and manufacturing.
Read more →A Unified Namespace (UNS) is transforming how life sciences and manufacturing companies manage and access real-time data. In this blog, we explore what a UNS is, how it works, and why it’s becoming essential for streamlining operations, ensuring compliance, and supporting digital transformation. Discover the key technologies involved, including MQTT, AVEVA PI, Ignition, and more, and learn how Réalta Technologies helps clients implement scalable, future-ready data architectures.
Read more →As proud Official Data Solutions Partners to Munster Rugby, we recently had the opportunity to spend a morning at the Munster Rugby High Performance Centre for a joint photoshoot. It was a great chance to capture some of the people and moments that represent this partnership — from the players and coaching staff to members of the Réalta Technologies team.
Read more →Data historians are essential to life sciences manufacturing, supporting regulatory compliance, process optimisation, and data integrity. In this article, we break down the most commonly used historian platforms — including AVEVA PI, Ignition, DeltaV, Canary, and GE Proficy — and explain how they’re used to manage and analyse critical time-series data in regulated environments.
Read more →Data integrity is critical for regulatory compliance in pharma and biotech. Learn how Realta Technologies helps manufacturing facilities meet FDA 21 CFR Part 11 and GxP standards through secure data management, automation, and advanced analytics.
Read more →AVEVA Connect is revolutionising industrial data management, providing seamless cloud integration, enhanced collaboration, and real-time analytics. Learn how Realta Technologies helps businesses implement and optimise AVEVA Connect for maximum efficiency.
Read more →With fluctuating labour costs and evolving remote work trends, resource placement and offshore strategies in life sciences and manufacturing are changing rapidly. Discover key market trends for 2025 and strategies to stay competitive.
Read more →Batch reporting and Review by Exception (RBE) are streamlining compliance in the pharmaceutical industry. Manufacturers can reduce delays, improve efficiency, and ensure regulatory compliance by automating the review process and focusing on exceptions. Discover how Réalta Technologies delivers customised solutions to transform batch reporting.
Read more →Understanding the roles of a Data Engineer, Data Scientist, and Data Analyst is crucial for effective data management. Learn how Réalta Technologies delivers all three services to help businesses capture, process, and analyse data for actionable insights.
Read more →Start the conversation
Talk to our team or take the Digital Maturity Assessment to understand where the greatest opportunities lie.
